SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Clown-Free Zone... sorry, no clowns allowed
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (154372)3/3/2002 1:52:13 PM
From: reaper  Read Replies (2) of 436258
 
but one would think that some significant portion of the SEPR market cap is based upon approval for the drug (especially since we can all see the excellent-looking abstracts). so if for some reason it doesn't get approved, the stock will do seriously not well.

i likely could have chosen my words a little better (the "make-or-break" reference) as yes, SEPR will not instantly go out of business if Soltara gets turned down. but the stock will take a large hit.

am i correct in my expectations for a 9 March timeline on FDA action??

Cheers
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News